Evidence map›Paper›PMID 31463888›Full record

ReviewJournal of gastrointestinal cancer2020

The Anticancer Efficiency of Citrullus colocynthis Toward the Colorectal Cancer Therapy.

Manal Khalid Abdulridha, Ali-H Al-Marzoqi, Abdolmajid Ghasemian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Biochemical Screening,Current pharmaceutical biotechnology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Molecules (Basel, Switzerland) · 2023
    Review
  8. Nanomaterials (Basel, Switzerland) · 2022
    Article
  9. Frontiers in pharmacology · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Manal Khalid AbdulridhaDepartment of Clinical Pharmacy, College of Pharmacy/Mustansiriyah University, Baghdad, Iraq.
Ali-H Al-MarzoqiDepartment of Biology, College of Sci for Women, University of Babylon, Hillah, Iraq.
Abdolmajid GhasemianDepartment of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran. majidghasemian86@gmail.com.ORCID http://orcid.org/0000-0002-1243-6341

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) remains a major cause of death worldwide. Chemotherapy is associated with some side effects during CRC treatment. Hence, proper employment of lower toxic and approaches exerting lowest side effects are essential. The Citrullus colocynthis (C. colocynthis) seems a potential anticancerous herbal medicine (HM) against CRC mostly via various efficient compounds.

methodsWe performed a literature review regarding the anticancer traits of C. colocynthis against CRC. The possible active compounds, mechanisms, and combination therapies in vitro and in vivo or clinical trials have been also stated where found. RESULTS AND

conclusionThe anticancerous effects of C. colocynthis has been via a variety of pathways including apoptotic pathways (increase in caspase-3 and inhibiting STAT3 function), antioxidant and anti-inflammatory (TNF-α, nitric oxide, and pro-inflammatory cytokines such as IL-6, IL-8, and IL-1α) traits, inhibition of Wnt/β-catenin signaling pathway, and antiangiogenesis and antimetastatic effects. Future studies will be promising regarding proper application of C. colocynthis compounds following their extraction.

Indexed as

AdultAgedCitrullus colocynthisColorectal NeoplasmsHerbal MedicineHumansMiddle AgedPlant ExtractsPlant ExtractsAnticancer therapyAntioxidantsCitrus colocynthisColorectal cancerHerbal medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.